No Detail Found!

Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment

Author(s)
Baolin Wang Internal Medicine-Neurology, The Third People's Hospital of Qingdao, Qingdao, China
Liang Zhong Internal Medicine-Neurology, The Third People's Hospital of Qingdao, Qingdao, China
Pingping Qiao Internal Medicine-Neurology, The Third People's Hospital of Qingdao, Qingdao, China
Zhenliang Ma Internal Medicine-Neurology, The Third People's Hospital of Qingdao, Qingdao, China
Abstract
As a  a1-adrenergic receptor antagonist, nicergoline can induce vasodilation and increase arterial blood flow. Its clinical application can effectively prevent and treat cognitive impairment and reduce cognitive decline and comprehensively improve patients' daily living ability and social function. The clinical efficacy of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment after stroke was analyzed. 120 patients with cognitive impairment after stroke were randomly divided into nicergoline group and Experience group. They were treated with nicergoline and nicergoline combined with oxiracetam respectively. Both groups were treated for one month. Montreal Cognitive Assessment Scale (MoCA) was used to evaluate the cognitive function of the two groups before and after treatment, and the clinical efficacy was compared. The results showed that the average score of MoCA in the combined group was (5.97±2.06), higher than that in the nicergoline group (3.53±1.44). The change of MoCA score was the most significant. There was significant difference between the nicergoline group and the combined group (t=4.21, P<0.01). The combined group had the highest effective rate and the total effective rate was 93.3%. Conclusion: Nicergoline and oxiracetam are effective drugs in the treatment of vascular cognitive impairment (VCI). The combined use of nicergoline and oxiracetam is better than that of nicergoline alone. The combined use of nicergoline and oxiracetam can significantly improve the severity of symptoms and quality of life in patients with vascular cognitive impairment after stroke. The clinical effect is definite.
Publication Details
Page(s) 417-422
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 33, Issue: S1, Year: 2020

Request the full text from PASTIC

Keywords
Oxiracetam, Stroke, Vascular cognitive impairment, nicergoline
References
Arriola A,Raquel FR,Xinia G,Salas G,Nutr D. .2018 .Blood concentrations of leptin and adiponectin in school children after the implementation of the model of prevention of childhood obesity "Pongale Vida". , 68(2) : 152-163.
Block T,Petrides G,Kushner H G .2017 .Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. J. Clini. Psycho., 37(5) : 505.
Carmen C,Maria P,Jorge RP,Nutr D. .2018 .Development and validation of scales to measure women's eating and satiation values: A critical factor in the treatment of obesity. , 68(2) : 141-151.
Dettogni A,Antonio T,Marcelo M,Mala D.,Sal Y. .2018 .Studying the structures of in silico designed novel antimalarial drugs having lesser GlideScore, Bolet. , 58(5) : 161-165.
Emir S,Sozen S,Bali I,GUrdal SO,Turan BC,Yıldırım O,Yetisyigit T .2014 .Outcome analysis of laporoscopic D1 and D2 dissection in patients 70 years and older with gastric cancer. Int. J. Clin. Exp. Med, 7(10) : 3501-3511.
Azevedo Eliane J,C Eliane J,Mala D.,Sal Y. .2018 .Principle and practice of infectious disease of humans. , 58(4) : 2-7.
Kich DM,Bitencourt S,Alves C,Silva J,Pinteus S,Pedrosa R,Laufer S R .2016 .Neuromodulatory effects of Calyptranthes grandifolia extracts against 6- hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. , 84(5) : 382-386.
Killick R,Ribe EM,Al-Shawi R,Malik B,Hooper C,Fernandes C C .2014 .Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wntPCP-JNK pathway. Mol Psychiatry, 19(4) : 88-98.
Kim MS,Lee JI,Lee WY,Kim S WY .2004 .Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease. Phytother. Res., 18(2) : 663-666.
Kim HY,Jeon H,Kim H,Koo S,Kim S S .2018 .Sophora flavescens Aiton decreases MPP+-induced mitochondrial dysfunction in SH-SY5Y cells. Front Aging Neurosci., 10(4) : 119.
Lazarevic-Pasti T,Leskovac A,Momic T,Petrovic S,Vasic V .2017 .Modulators of acetyl cholinesterase activity: From Alzheimer's disease to anti-cancer drugs. Curr. Med, 24(30) : 3283-3309.
Lansac F,Maria B,Oliveira F B,Mala D.,Sal Y. .2018 .Identification and sequence analysis of Aedes aegypti mosquitoes. , 58(6) : 147-151.
Lee JK,Kim NJ .2017 .Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease. Molecules, 22(8) : 1287.
Li S,Sun X,Xu L,Sun R,Ma Z,Deng X,Liu B,Fu Q,Qu R Q .2017 .Baicalin attenuates in vivo and in vitro hyperglycemia-exacerbated ischemia/reperfusion injury by regulating mitochondrial function in a manner dependent on AMPK. Eur. J. Pharmacol., 815(2) : 118-126.
Lin MT,Beal MF .2006 .Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443 : 787-795.
Liu Z,Zhou T,Ziegler AC,Dimitrion P,Zuo L P .2017 .Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid Med, 17(2) : 2525967.
Luo Y .2001 .Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer's disease. J. Alzheimers. Dis., 3(4) : 401-407.
Marmitt DJ,Bitencourt S,Silva AC,Rempel C,Goettert MI C .2018 .Medicinal plants used in Brazil public health system with neuroprotective potential: A systematic review. Bol. Latinoam. Caribe Plant Med, 17(2) : 84-103.
McIlwain DR,Berger T,Mak TW .2013 .Caspase functions in cell death and disease. Cold Spring Harb Perspect. Biol, 5(4) : a008656.
Mensor FS,Menezes CC,Leitao AS,Reis TC,dos Santos CS,Coube SG .2001 .Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method. Phytother. Res., 15(1) : 127-130.
Miloso M,Scuter A,Foudah D,Tredici G .2008 .MAPKs as mediators of cell fate determination: An approach to neurodegenerative diseases. Curr. Med, 15(6) : 538-548.
Mosmann T .1983 .Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65(1-2) : 55-63.
Nabavi SF,Braidy N,Orhan IE,Nabavi SM .2016 .Rhodiola rosea L. and Alzheimer's disease: From farm to pharmacy. Phytother. Res., 30(4) : 30-36.
Nordberg A .2006 .Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis, 20(2 Suppl 1) : S12-S18.
Park KR,Nam D,Yun HM,Lee SG,Jang HJ,Sethi G,Cho SK,Ahn KS .2011 .β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett., 312(1) : 178-188.
Rodriguez R,Armando C,Maribel RL C,Nutr D. .2018 .Relationship between body composition and blood leptin concentration in female college students. Archi, 68(2) : 175-183.
Rochin M,Jesus J,Ramirez K,Rangel P K,Nutr D. .2018 .Increase in nutritional value, antioxidant activity and inhibitory potential of alpha-glucoside in brownies from cooked legumes, Archi. , 68(2) : 164-174.
Shi Y,Zhu Q Y,Bolet D.,Mala Y.,Sal Y. .2018 .Detection of Methylene tetra hydrofolate Reductase Gene C677T Mutation by PCRRFLP. , 58(6) : 152-158.
Singh DP,Singh SS,Singh S,Shrivastava AK,Sinha K. .2016 .Clinical profile of acute coronary syndrome (ACS) in young adults of North Indian population. J. Assoc. Physicians India, 64(1) : 33.
Wozakowska-Kapłon Trzeciak P,B Trzeciak P .2016 .Comparison of Inhospital and 12- and 36-Month Outcomes After Acute Coronary Syndrome in Men Versus Women <40 Years (from the PL-ACS Registry). Am. J. Cardiol., 118(9) : 1300-1305.
Virginia MA,Laura V,Hernandez-Madrigal J,Nutr Archi. Latin. D. .2018 .Physical and nutritional characterization of tuber meal of "Malanga" (Colocasia esculenta L. Schott) of Actopan. , 68(2) : 175-183.
Zhou Y,Lv C,Wang Y C,Mala D.,Sal Y. .2018 .Emergency Nursing Intervention Procedure for Cerebral Infarction Thrombolysis Patients with Neurological Defects. , 58(5) : 148-153.
0

Citations

0

Downloads

10

Views